Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

BioTAK Blood Test for Broken Heart Syndrome

Analysis based on 6 articles · First reported Sep 01, 2026 · Last updated Sep 21, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The BioTAK score points to a growing market for non-invasive cardiac diagnostics, potentially reducing demand for some catheterization lab procedures while expanding the use of specialized blood biomarker testing. Commercialization remains years away pending outcome trials, so near-term impact on device makers, hospital operators and diagnostics companies is limited but directionally supportive of the less-invasive cardiac assessment trend.

healthcare medical diagnostics biotechnology

An international research team led by scientists at the University of Zurich and University Medical Center Greifswald developed and validated the BioTAK score, a blood-based diagnostic tool that distinguishes Takotsubo syndrome, commonly known as broken heart syndrome, from a genuine heart attack. Takotsubo syndrome is a sudden weakening of the heart muscle usually triggered by intense emotional or physical stress, and it most often affects postmenopausal women. It accounts for roughly 2 percent of patients initially thought to be having a heart attack, rising to as many as one in ten women presenting with acute coronary syndrome. Because symptoms, electrocardiogram changes and elevated cardiac enzymes overlap almost completely with a heart attack, patients currently must undergo invasive cardiac catheterization to rule out blocked coronary arteries. The BioTAK score combines biological sex with several blood biomarkers, including NT-proBNP, PAM, sLOX-1 and LDL cholesterol, selected using artificial intelligence. In an independent validation group of nearly 1,800 patients, the score correctly classified close to 90 percent of participants before catheterization. Two of the biomarkers point toward the brain-heart axis, suggesting Takotsubo syndrome develops through mechanisms independent of atherosclerosis. The study, published in the European Heart Journal, drew on more than 3,600 patients from the Swiss SPUM-ACS Registry and the International Takotsubo (InterTAK) Registry. Researchers including Florian A. Wenzl, Victor Schweiger, Thomas Lüscher and Christian Templin stressed that the score is not a substitute for cardiac catheterization when medically necessary, and that further trials are needed to determine whether it improves patient outcomes in routine care.

60 Florian A. Wenzl co-authored study
60 Thomas Lüscher co-authored study
60 Christian Templin co-authored study
55 Victor Schweiger co-authored study
oth
Co-last author Christian Templin, director of its Department of Internal Medicine B and founder of the InterTAK Registry, contributed key registry data and emphasized the score is not a substitute for catheterization.
Importance 70.0 Sentiment 15.0
per
Co-first author from the University of Zurich and University of Oxford who stated the score identifies patients with remarkable accuracy before catheterization.
Importance 70.0 Sentiment 10.0
per
Co-last author from Imperial College London and King s College London who described the score as translating complex disease mechanisms into a practical diagnostic tool.
Importance 70.0 Sentiment 10.0
per
Co-last author and founder of the InterTAK Registry who stressed the score is not a substitute for cardiac catheterization when medically necessary.
Importance 65.0 Sentiment 10.0
per
Co-first author from University Hospital of Zurich who noted the biomarkers provide insight into the biological processes distinguishing Takotsubo syndrome from a classic heart attack.
Importance 55.0 Sentiment 10.0
oth
Collaborated closely with the University of Zurich on the study, contributing to the development and validation of the BioTAK score.
Importance 50.0 Sentiment 15.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.